DE:C68 / Crescent Biopharma, Inc. - Net Long/Short Value

Crescent Biopharma, Inc.
DE ˙ DB ˙ US14888D2080
DE:C68 / Crescent Biopharma, Inc. - Net Long/Short Value
Halaman ini menyediakan nilai bersih long/short untuk setiap kepemilikan institusional yang dilaporkan melalui pengajuan 13F atau NPORT. Untuk menghitung nilai bersih long/short, kami menambahkan nilai ekuitas ke nilai opsi beli (call option) dan mengurangi nilai opsi jual (put option). Dana yang melaporkan posisi short-borrowed akan melaporkan nilai ekuitas sebagai negatif. Posisi long bersih akan memiliki angka positif di kolom long/short bersih, dan posisi short bersih akan memiliki nilai negatif di kolom tersebut.
Pemilik Nilai Ekuitas
($1000)
Nilai Panggilan
($1000)
Masukkan Nilai
($1000)
Posisi Long/Short Bersih
($1000)
Soleus Capital Management, L.P.
Bvf Inc/il
Bank Of America Corp /de/
VR Adviser, LLC
Jefferies Financial Group Inc.
Fairmount Funds Management LLC
Frazier Life Sciences Management, L.P.
Driehaus Capital Management Llc
BlackRock, Inc.
Bnp Paribas Arbitrage, Sa
Deep Track Capital, LP
Wellington Management Group Llp
Barclays Plc
Morgan Stanley
Blackstone Group Inc
Royal Bank Of Canada
Commodore Capital Lp
UBS Group AG
Fmr Llc
Braidwell Lp
Perceptive Advisors Llc
Paradigm Biocapital Advisors LP
Adage Capital Partners Gp, L.l.c.
Raymond James Financial Inc
Group One Trading, L.p.
Tang Capital Management Llc
Affinity Asset Advisors, LLC
Boxer Capital Management, LLC
SBI Securities Co., Ltd.
Logos Global Management LP
Other Listings
US:CBIO US$ 14.24
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista